GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (STU:1FG) » Definitions » Capital Expenditure

FibroGen (STU:1FG) Capital Expenditure : €-0.24 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is FibroGen Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

FibroGen's cash flow for capital expenditures for the three months ended in Mar. 2025 was €-0.02 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.24 Mil.

FibroGen Capital Expenditure Historical Data

The historical data trend for FibroGen's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Capital Expenditure Chart

FibroGen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.28 -26.72 -36.57 -2.31 -0.25

FibroGen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.01 -0.07 -0.14 -0.02

FibroGen Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FibroGen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (STU:1FG) » Definitions » Capital Expenditure
Comparable Companies
ALGS LVTX CYCC BOLD PPCB AAGH PLUR ANTX LTRN MLEC VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
FGEN:USA FGEN:Mexico 0IL8:UK 1FG:Germany
Address
350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94158
Website
https://www.fibrogen.com
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

FibroGen Headlines

No Headlines